Last updated: June 19, 2026
LYNAVOY suppliers: who manufactures and supplies the drug, APIs, and key components?
LYNAVOY’s commercial supply chain depends on the manufacturer(s) listed for the specific FDA product strength and dosage form in drug distribution records and labeling. Without the exact LYNAVOY presentation (strength and dosage form), the identifying manufacturer and supplier stack cannot be stated accurately.
What companies supply LYNAVOY (API, drug product, and finished dosage forms)?
No complete, verifiable supplier mapping for LYNAVOY (API manufacturer, contract drug substance makers, and contract drug product manufacturers) can be produced from the information provided. LYNAVOY’s supply chain is presentation-specific and is typically reflected in FDA product labeling, the Orange Book listing, and distribution/labeler data tied to NDCs.
Are LYNAVOY API makers the same as the drug product manufacturers?
No reliable answer can be produced without the exact LYNAVOY NDC(s) or the FDA label “Manufactured for/Distributed by” strings for the specific strength/dosage form.
Which contract manufacturers typically supply a marketed oral/specialty drug like LYNAVOY?
No reliable answer can be produced for LYNAVOY without source documents that name the labeled manufacturer(s) for the finished drug.
What is the Orange Book status of LYNAVOY and what does it imply about suppliers?
No LYNAVOY Orange Book listing (application number, listed drug, NDA/BLA holder, and patent-protected manufacturing methods) can be cited from the information provided. Supplier identification for branded product distribution and NDA ownership is tied to the Orange Book “Applicant” and “Manufacturer” fields.
Who is the NDA holder for LYNAVOY and how does that affect supplier selection?
No NDA holder for LYNAVOY can be cited from the information provided. The NDA holder typically controls branded supply through direct manufacturing and/or contract manufacturing agreements.
What generic or biosimilar entry risks change LYNAVOY supplier leverage?
No LYNAVOY exclusivity or patent-expiration timeline can be stated without the Orange Book/BLA framework for the product. Supplier leverage in the presence of generic competition depends on whether additional applicants can qualify for approval using the same or different manufacturing sites.
How do LYNAVOY labeling and NDC-level data identify manufacturers and distributors?
No NDC-level mapping can be produced without the specific LYNAVOY strength/dosage form. Manufacturer and distributor names differ by NDC even within the same branded product family.
Key takeaways
- Supplier identification for LYNAVOY requires the exact NDC-specific FDA product and labeling strings.
- Without the presentation (strength and dosage form) and the corresponding label/manufacturer fields, it is not possible to state API and finished-dose suppliers accurately.
FAQs
- How do I identify the finished drug manufacturer for LYNAVOY from FDA labeling?
- Where do LYNAVOY’s API suppliers appear if different from the drug product maker?
- Does LYNAVOY use multiple manufacturing sites across NDCs?
- How does Orange Book “listed drug” data connect to who manufactures LYNAVOY?
- What data sources typically show LYNAVOY supplier changes over time?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
